Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RXSD Rexall Sundown -- Ignore unavailable to you. Want to Upgrade?

To: Adelantado who wrote (202)	12/9/1998 8:32:00 PM
From: brent gephart	Read Replies (1) \| Respond to of 327

SOURCE: Rexall Sundown, Inc. Rexall Sundown and ProteoTech Enter Exclusive Licensing Agreement To Launch New Dietary Supplements for Alzheimer's Disease biz.yahoo.com Wednesday December 9, 12:50 pm Eastern Time Company Press Release BOCA RATON, Fla., Dec. 9 /PRNewswire/ -- Rexall Sundown, Inc. (Nasdaq: RXSD - news) and ProteoTech, Inc., a private Redmond, WA-based biotechnology company, have signed an exclusive worldwide licensing agreement for the introduction of an orally available dietary supplement ingredient that in laboratory tests has been shown to prevent formation and disrupt brain amyloid deposits believed to play a central role in Alzheimer's disease. Under terms of the agreement, ProteoTech has granted Rexall Sundown an exclusive license in the dietary supplement field of use to manufacture, sell, and distribute products based upon PTI-00703™, a proprietary ingredient discovered by ProteoTech to have promising amyloid-inhibitory characteristics. The first of these products is now being introduced commercially under the brand name Sundown Neurosharp™, with PTI-00703™ and ginkgo biloba. ProteoTech will provide continuing research and development expertise to Rexall for this and other amyloid-inhibiting ingredients derived from PTI- 00703™ for use as dietary supplements. ProteoTech and Rexall Sundown have also agreed to initiate a human clinical trial early next year to test dietary supplement formulations containing PTI-00703™ on patients with early-to- moderate Alzheimer's disease. The license agreement follows a July announcement by researchers from the University of Washington and ProteoTech who reported the discovery of PTI- 00703™ at the Sixth International Conference of Alzheimer's Disease and Related Disorders in Amsterdam. In vitro testing showed that PTI-00703™ acts as a potent inhibitor of Alzheimer's disease amyloid formation and growth. These researchers also reported that PTI-00703™ demonstrates an ability to disrupt and/or dissolve pre-formed Alzheimer's disease amyloid fibrils in vitro. Although the research team cautioned that additional testing is needed, current findings would seem to indicate that use of PTI-00703™ when taken as a dietary supplement may benefit human patients with Alzheimer's disease at various stages of disease. ''We are pleased to have forged this alliance with ProteoTech, whose research activities have focused on research pertaining to Alzheimer's disease for over 15 years,'' stated Debbie DeSantis, Vice President, Product Development for Rexall Sundown. ''Their commitment to consumer needs through scientific and clinical research and development is well aligned with our Company's mission to develop science-driven nutritional products. In addition to traditional approaches, dietary supplements can also provide important preventative and restorative health benefits responsive to fundamental health concerns worldwide,'' she added. ''This agreement is an important milestone for ProteoTech,'' said Alan D. Snow, Ph.D., one of the scientific co-founders of ProteoTech Inc. ''We are pleased to have entered into a license agreement with Rexall Sundown due to its market prominence and its underlying science-driven approach to dietary supplement formulation. ProteoTech's main business focus is the development of therapeutics and diagnostics for human disease based upon proteoglycan technologies. Licensing PTI-00703™ for dietary supplement use will enable the public to have access to our proprietary technology with potential preventative health benefits, and to further support our continued development efforts as well,'' he said. Rexall Sundown, Inc. develops, manufactures and distributes vitamins, nutritional supplements and other consumer health products. Visit the Company's web site at www.rexallsundown.com . ProteoTech, Inc. is a drug discovery company focused on therapeutics and diagnostics for human disease utilizing proteoglycan technologies. The ''amyloid diseases'' all involve the accumulation of specific proteoglycans believed to augment the amyloid process and inhibit the body's natural ability to remove unwanted ''amyloid deposits.'' Proteoglycans are synthesized by virtually all cells of the body and play significant roles in the pathogenesis of a number of human diseases, including Alzheimer's, Down's syndrome, cancer, arthritis, atherosclerosis, heart disease and AIDS. Visit the Company's web site at www.proteotech.com . This press release may contain ''forward-looking statements'' as such term is defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases, which represents the Company's interpretation or beliefs. These forward- looking statements, by their nature involve substantial risks and uncertainties, certain of which may be beyond the Company's control and actual results may differ materially depending on a variety of important factors including uncertainties related to acquisitions, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, reliance on independent distributors of Rexall Showcase, competition and other factors described in the Company's filings with the Securities and Exchange Commission.